Leadership

Guy Macdonald

President and Chief Executive Officer

Jacques Dumas, Ph.D.

Chief Scientific Officer

Larry Edwards

Chief Operating Officer

Maria Stahl

General Counsel

Larry Tsai, M.D.

Chief Medical Officer

Christopher Watt

Senior Vice President, Finance

Guy Macdonald

President and Chief Executive Officer

Guy Macdonald has served as President and Chief Executive Officer of Tetraphase and has been a member of the Board of Directors since January 2008. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President, Operations, at Idenix Pharmaceuticals, Inc. Prior to joining Idenix, he served in various positions at Merck & Co., Inc., from 1981 to 2003, including Vice President for Anti-Infective and Hospital Products. Mr. Macdonald currently serves as Chairman of the Board of Directors of Scynexis, Inc. Mr. Macdonald received an Honours Degree in biochemistry from Dundee University in Dundee, Scotland.

Jacques Dumas, Ph.D.

Chief Scientific Officer

Jacques Dumas, Ph.D., has served as Chief Scientific Officer since July 2015. Dr. Dumas has over 20 years of research and development experience, from discovery to clinical proof-of-concept, and is a co-inventor of two marketed drugs, Nexavar® and Stivarga®. Before joining Tetraphase, Dr. Dumas served as Vice President, Idenix, at Merck Research Laboratories. Prior to that, he was also Chief Scientific Officer at Idenix Pharmaceuticals, Inc. From 2007 to 2014, Dr. Dumas worked for AstraZeneca, most recently as Vice President and Head of Strategy and External Collaborations for the AstraZeneca Small Molecule Infectious Diseases Unit. Prior to AstraZeneca, Dr. Dumas worked at Bayer HealthCare for 15 years, most recently as Director of Medicinal Chemistry. He received his Ph.D. in organic chemistry from Paris VI University in France and completed a Postdoctoral Fellowship at Stanford University.

Larry Edwards

Chief Operating Officer

Larry Edwards has served as Chief Operating Officer since March 2018. Mr. Edwards joined Tetraphase in July 2015 as Vice President of Marketing, became Vice President of Commercial Operations in January 2016, and most recently served as Chief Commercial Officer from January 2017 to February 2018. Prior to joining Tetraphase, Mr. Edwards served as Senior Director of Marketing, Gram-negative Franchise, with Cubist Pharmaceuticals, Inc., from April 2014 to July 2015 (Cubist acquired by Merck & Co., Inc.). From 2010 to 2014, he served as Global Marketing Director, Clostridium difficile and New Infectious Disease Products, with Merck & Co., Inc., where he also served as Associate Director of Vaccines and Infectious Diseases from 2007 to 2010, and held various management training and sales positions of increasing responsibility from 1999 to 2007. Mr. Edwards received a B.S. in business and healthcare administration from Ohio University.

Maria Stahl

General Counsel

Maria Stahl has served as Senior Vice President and General Counsel since March 2015. Prior to joining Tetraphase, Ms. Stahl served as Senior Vice President, General Counsel, and Secretary of Idenix Pharmaceuticals, Inc. from October 2010 to August 2014. Ms. Stahl previously served at Idenix as Vice President, Associate General Counsel from February 2008 to November 2009, and as Assistant General Counsel from February 2007 to February 2008. Prior to rejoining Idenix, Ms. Stahl served as General Counsel of Zipcar, Inc., from November 2009 to October 2010. From February 2005 to February 2007, she served as Vice President, Corporate Counsel of Capital Crossing Bank. Prior to that, Ms. Stahl was at Wilmer Cutler Pickering Hale and Dorr LLP from 1997 to 2005. She received a B.A. from Providence College and a J.D. from Yale Law School.

Larry Tsai, M.D.

Chief Medical Officer

Larry Tsai, M.D., has served as our Chief Medical Officer since January 2018. Dr. Tsai joined the company in 2014 as Senior Medical Director, then was named Vice President, Clinical Development, in 2015. From 2002 to 2011, Dr. Tsai held various positions at Aeris Therapeutics, Inc., most recently serving as Vice President of Research and Development. Dr. Tsai holds a B.S. in biology from Stanford University and an M.D. from the Health Sciences and Technology program at Harvard Medical School. He is board certified in critical care medicine, internal medicine, and pulmonary disease. Dr. Tsai is still actively engaged in clinical practice, which affords him real-world insights into the challenges and opportunities related to antibiotic resistance.

Christopher Watt

Senior Vice President, Finance

Christopher Watt has served as our Senior Vice President of Finance since January 2017, previously serving as Vice President of Finance upon joining Tetraphase in July 2015. Prior to joining the company, Mr. Watt spent 10 years at Biogen, Inc., most recently as Senior Director, Global Commercial Finance. From 2009 to 2010, Mr. Watt served as the Finance Director of Biogen for the UK and Ireland affiliates, and from 2006 to 2009 as Director of Business Planning, International, based in Switzerland. Prior to Biogen, Mr. Watt spent four years in various financial planning and analysis roles at InterSystems Corporation. Mr. Watt holds a B.A. from Colby College and an M.B.A. from the University of Michigan.

Board of Directors

L. Patrick Gage, Ph.D.

Chairman

L. Patrick Gage, Ph.D., has served as a member of our Board of Directors and as Chairman of our Board of Directors since...

Garen Bohlin

 

Garen Bohlin has served as a member of our Board of Directors since July 2010. Since May 2012, Mr. Bohlin has served on the Board of...

Jeffrey A. Chodakewitz, M.D.

 

Jeffrey A. Chodakewitz, M.D., has served as a member of our Board of Directors since June 2014. Since April 2018, Dr. Chodakewitz...

John G. Freund, M.D.

 

John G. Freund, M.D., has served as a member of our Board of Directors since October 2012. Dr. Freund co-founded Skyline...

Gerri Henwood

 

Gerri Henwood has served as a member of our Board of Directors since April 2015. Since 2008, Ms. Henwood has served as President...

Guy Macdonald

Tetraphase

Guy Macdonald has served as President and Chief Executive Officer of Tetraphase and has been a member of the Board of Directors...

Nancy J. Wysenski

 

Nancy J. Wysenski has served as a member our Board of Directors since March 2014. From December 2009 through June...

L. Patrick Gage, Ph.D.

Chairman

L. Patrick Gage, Ph.D., has served as a member of our Board of Directors and as Chairman of our Board of Directors since December 2011. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry. From 1998 to 2002, Dr. Gage served as President of Wyeth Research (now part of Pfizer, Inc.). Prior to joining Wyeth Research, he served in various positions at Genetics Institute, Inc., a biotechnology company, from 1989 to 1998, first as Head of Research and Development, then as Chief Operating Officer, and eventually as President. From 1971 to 1989, Dr. Gage served in various positions in research management with Hoffmann-La Roche Inc., a pharmaceutical company, most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served on the Board of Directors of Cytokinetics, Inc., a publicly traded biopharmaceuticals company, since November 2009 and as Chairman of its Board of Directors since March 2010. Previously he served on the Board of Directors of PDL BioPharma, Inc., a publicly traded biotechnology company, from 2003 through 2008, as the Chairman of its Board of Directors in 2007, and as Interim Chief Executive Officer from 2007 to 2008. Dr. Gage currently serves on the Board of Directors of two nonprofit organizations, the Marine Biological Laboratory and The Wistar Institute. Dr. Gage also currently serves in an advisory role to other private companies and organizations. Dr. Gage received a B.S. in physics from the Massachusetts Institute of Technology and a Ph.D. in biophysics from the University of Chicago.

Garen Bohlin

Garen Bohlin has served as a member of our Board of Directors since July 2010. Since May 2012, Mr. Bohlin has served on the Board of Directors and as a consultant to multiple life sciences companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., a biotechnology company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biotechnology company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the Board of Directors of Collegium Pharmaceutical, Inc., Karyopharm Therapeutics Inc., and Proteon Therapeutics, Inc., all publicly traded biotechnology companies. He also served on the Board of Directors for Acusphere, Inc., a specialty pharmaceutical company that was a publicly traded company, from 2005 to 2014, SpringLeaf Therapeutics, Inc., a private biotechnology company, from 2010 to 2013, and Precision Dermatology, Inc., a private dermatology company, from 2012 to 2014. Mr. Bohlin received a B.S. in accounting and finance from the University of Illinois.

Independent Director

Chairman of the Finance and Audit Committee

Jeffrey A. Chodakewitz, M.D.

Jeffrey A. Chodakewitz, M.D., has served as a member of our Board of Directors since June 2014. As of August 2018, Dr. Chodakewitz serves on the Board of Directors of resTORbio, Inc., a biopharmaceutical company focused on age-related diseases. He also currently holds the position of Executive Vice President, Clinical Medicine and External Innovation at Vertex Pharmaceuticals, Inc. From January 2014 to March 2018, Dr. Chodakewitz served as Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer of Vertex. Prior to joining Vertex, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles, including Vice President of Clinical Research—Infectious Diseases and Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy (Infectious Diseases, Respiratory/Immunology). Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the VA Connecticut Healthcare System in West Haven, Connecticut, and held various academic positions at Yale University and New York University schools of medicine. Dr. Chodakewitz is a Diplomat of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Infectious Disease, and is a member of the Infectious Diseases Society of America (IDSA) and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He received a B.S. in biochemistry from Yale University, cum laude, and an M.D. from the Yale University School of Medicine.

Independent Director

Member of the Compensation Committee

John G. Freund, M.D.

John G. Freund, M.D., has served as a member of our Board of Directors since October 2012. Dr. Freund co-founded Skyline Ventures in 1997 and has served as a Managing Director at Skyline since its founding. Prior to Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995, he co-founded Intuitive Surgical, Inc. a medical device company, and served on its Board of Directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corp., a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the Board of Directors of Collegium Pharmaceutical, Inc., a publicly traded biotechnology company, since 2014, and Proteon Therapeutics, Inc., a publicly traded biotechnology company, since 2014. Dr. Freund also serves on the Board of Directors of six U.S.-registered investment funds managed by Capital Research and Management. He also previously served on the Board of Directors of a number of publicly traded companies, including XenoPort, Inc., a biopharmaceutical company, where he served as Chairman of the Board; MAP Pharmaceuticals, Inc., a biopharmaceutical company; Hansen Medical, Inc., a medical device company; Mako Surgical Corp., a medical device company; and Concert Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School.

Independent Director

Member of the Nominating and Governance Committee

Member of the Finance and Audit Committee

Gerri Henwood

Gerri Henwood has served as a member of our Board of Directors since April 2015. Since 2008, Ms. Henwood has served as President, Chief Executive Officer, and Director of Recro Pharma, Inc., a publicly traded specialty pharmaceutical company developing acute care products, including non-opioid therapeutics for the treatment of acute pain. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, or MCG. She is the co-founder of Auxilium Pharmaceuticals, Inc. and served as its President, Chief Executive Officer, and Director from 1999 to 2006. Prior to cofounding Auxilium, in 1985, Ms. Henwood founded and was President and Chief Executive Officer of IBAH, Inc., a publicly traded contract research organization that was acquired by Omnicare, Inc. Ms. Henwood began her career with Smith, Kline & French, now part of GlaxoSmithKline plc, in the pharmaceutical management program. She held many positions there, including Head of Regulatory and Medical Affairs for U.S. Business and Group Director of Marketing in the International Pharmaceutical Division. Ms. Henwood holds a B.S. in biology from Neumann University.

Independent Director

Member of the Compensation Committee

Guy Macdonald

Tetraphase

Guy Macdonald has served as President and Chief Executive Officer of Tetraphase and has been a member of the Board of Directors since January 2008. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President, Operations, of Idenix Pharmaceuticals, Inc. Prior to joining Idenix, he served in various positions at Merck & Co., Inc., from 1981 to 2003, most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald currently serves as Chairman of the Board of Directors of Scynexis, Inc. Mr. Macdonald received an Honours Degree in biochemistry from Dundee University in Dundee, Scotland.

Nancy J. Wysenski

Nancy J. Wysenski has served as a member our Board of Directors since March 2014. From December 2009 through June 2012, Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals, Inc. a publicly traded pharmaceutical company. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals Inc., a 1,200-person specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources, and various business development initiatives. Prior to her time at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves as a Director of Alkermes plc, a publicly traded biopharmaceutical company, and of Dova Pharmaceuticals, Inc., a publicly traded pharmaceutical company. She served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association, and is a founder of the Research Triangle Park Chapter. Ms. Wysenski received a B.S.N. from Kent State University and an M.B.A. from Baldwin-Wallace College.

To:

Please enter a valid email address.

From:

Please enter a valid email address.

Share information about Tetraphase

Cancel

Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.

OK